Publications

Exploratory Biomarker Analyses of Fairlane, a Double-Blind Placebo (Pbo)-Controlled Randomized Phase Ii Trial of Neoadjuvant Ipatasertib (Ipat) plus Paclitaxel (Pac) for Early Triple-Negative Breast Cancer (Tnbc)

AuthID
P-00Q-YS7

Author(s)

Wongchenko, MJ

Oliveira, M

Saura, C

Nuciforo, P

Calvo, I

Andersen, J

Coelho, JIP

Gil, MG

Bermejo, B

Patt, DA

Ciruelos, E

Singel, SM

Maslyar, DJ

Xu, N

de la Pena, L

Baselga, J

Gendreau, S

Isakoff, SJ

Document Type

Abstract

Year published

2019

Published

in CANCER RESEARCH, ISSN: 0008-5472

Volume: 79, Issue: 4

Conference

San Antonio Breast Cancer Symposium, Date: DEC 04-08, 2018, Location: San Antonio, TX

Indexing

Wos^®

Google Scholar^®

Metadata
Sources

Publication Identifiers

DOI: 10.1158/1538-7445.sabcs18-p2-08-19

Wos: WOS:000478677000438

Source Identifiers

ISSN: 0008-5472

Export Publication Metadata

Marked List

Add to Marked List

Info

At this moment we don't have any links to full text documens.

Exploratory Biomarker Analyses of Fairlane, a Double-Blind Placebo (Pbo)-Controlled Randomized Phase Ii Trial of Neoadjuvant Ipatasertib (Ipat) plus Paclitaxel (Pac) for Early Triple-Negative Breast Cancer (Tnbc)

Useful Links

Get Help

Federated Authentication (Click on the image)

Exploratory Biomarker Analyses of Fairlane, a Double-Blind Placebo (Pbo)-Controlled Randomized Phase Ii Trial of Neoadjuvant Ipatasertib (Ipat) plus Paclitaxel (Pac) for Early Triple-Negative Breast Cancer (Tnbc)

Useful Links

Get Help